Cargando…

Propofol pharmacokinetics in China: A multicentric study

OBJECTIVE: A multicenter population pharmacokinetics study of propofol was performed to establish a new population model. MATERIALS AND METHODS: Three thousand two hundred and fifty-nine blood samples of 220 participants were measured by HPLC-UV or HPLC-FLU or GC-MS. Target-controlled infusion after...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Hong-bo, Li, Jin-heng, Rui, Jian-zhong, Zheng, Hong, Zhang, Xin-an, Chi, Xin-jin, Chen, Wen-ying, Xu, Jian-guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371467/
https://www.ncbi.nlm.nih.gov/pubmed/22701254
http://dx.doi.org/10.4103/0253-7613.96346
_version_ 1782235202643296256
author Ye, Hong-bo
Li, Jin-heng
Rui, Jian-zhong
Zheng, Hong
Zhang, Xin-an
Chi, Xin-jin
Chen, Wen-ying
Xu, Jian-guo
author_facet Ye, Hong-bo
Li, Jin-heng
Rui, Jian-zhong
Zheng, Hong
Zhang, Xin-an
Chi, Xin-jin
Chen, Wen-ying
Xu, Jian-guo
author_sort Ye, Hong-bo
collection PubMed
description OBJECTIVE: A multicenter population pharmacokinetics study of propofol was performed to establish a new population model. MATERIALS AND METHODS: Three thousand two hundred and fifty-nine blood samples of 220 participants were measured by HPLC-UV or HPLC-FLU or GC-MS. Target-controlled infusion after single bolus or continuous infusion was applied for propofol anesthesia. The samples were taken from 2 to 1500 min. The concentration-time profiles were analyzed by nonlinear mixed effect model (NONMEM) with first order estimation method. The inter-individual variability and the residual variability were described by exponential model and constant coefficient variation model. The stepwise modeling strategy using PsN was applied for covariate modeling. The criteria of forward addition and backward elimination were (α = 0.01 and α = 0.005, χ(2), df = 1). The final model was evaluated by bootstrap using PDx and visual predictive check using PsN. 500 bootstraps and 1000 simulation were run. RESULT: The propofol population model was described by 3-compartment model with inter-individual variability of CL, V(1), Q(2,) and Q(3) describing by exponential model. The inter-individual variability of V(2), V(3) were not included because it is reported that the parameter was near its boundary. The typical value of CL, V1, Q2, V2, Q3 and V3 were 1.28 L · min(-1), 10.1 × (age/44)-0.465 × (1 + 0.352 × sex) L, 0.819 L · min(-1), 36.0 L, 0.405 × (bodyweight/60)1.58 L · min(-1) and 272 L, respectively. Coefficients of inter-individual variability of CL, V1, Q2 and Q3 were 30.5%, 35.6%, 43.7% and 66.9%, respectively, and the coefficients of variation of HPLC-UV, GC-MS and HPLC-FLU were 13.3%, 16.9% and 24.2%, respectively. The bootstrap evaluation showed that the final model parameter estimates were within ± 3.39% compared with bootstrap median. The curves of observations percentiles were distributed within the corresponding 95 prediction percentiles by the visual predictive check. CONCLUSION: The three-compartment model with first-order elimination could describe the pharmacokinetics of propofol fairly well. The involved fixed effects are age, body weight and sex. The population model was evaluated to be stable by bootstrap and visual predictive check.
format Online
Article
Text
id pubmed-3371467
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-33714672012-06-14 Propofol pharmacokinetics in China: A multicentric study Ye, Hong-bo Li, Jin-heng Rui, Jian-zhong Zheng, Hong Zhang, Xin-an Chi, Xin-jin Chen, Wen-ying Xu, Jian-guo Indian J Pharmacol Short Communication OBJECTIVE: A multicenter population pharmacokinetics study of propofol was performed to establish a new population model. MATERIALS AND METHODS: Three thousand two hundred and fifty-nine blood samples of 220 participants were measured by HPLC-UV or HPLC-FLU or GC-MS. Target-controlled infusion after single bolus or continuous infusion was applied for propofol anesthesia. The samples were taken from 2 to 1500 min. The concentration-time profiles were analyzed by nonlinear mixed effect model (NONMEM) with first order estimation method. The inter-individual variability and the residual variability were described by exponential model and constant coefficient variation model. The stepwise modeling strategy using PsN was applied for covariate modeling. The criteria of forward addition and backward elimination were (α = 0.01 and α = 0.005, χ(2), df = 1). The final model was evaluated by bootstrap using PDx and visual predictive check using PsN. 500 bootstraps and 1000 simulation were run. RESULT: The propofol population model was described by 3-compartment model with inter-individual variability of CL, V(1), Q(2,) and Q(3) describing by exponential model. The inter-individual variability of V(2), V(3) were not included because it is reported that the parameter was near its boundary. The typical value of CL, V1, Q2, V2, Q3 and V3 were 1.28 L · min(-1), 10.1 × (age/44)-0.465 × (1 + 0.352 × sex) L, 0.819 L · min(-1), 36.0 L, 0.405 × (bodyweight/60)1.58 L · min(-1) and 272 L, respectively. Coefficients of inter-individual variability of CL, V1, Q2 and Q3 were 30.5%, 35.6%, 43.7% and 66.9%, respectively, and the coefficients of variation of HPLC-UV, GC-MS and HPLC-FLU were 13.3%, 16.9% and 24.2%, respectively. The bootstrap evaluation showed that the final model parameter estimates were within ± 3.39% compared with bootstrap median. The curves of observations percentiles were distributed within the corresponding 95 prediction percentiles by the visual predictive check. CONCLUSION: The three-compartment model with first-order elimination could describe the pharmacokinetics of propofol fairly well. The involved fixed effects are age, body weight and sex. The population model was evaluated to be stable by bootstrap and visual predictive check. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3371467/ /pubmed/22701254 http://dx.doi.org/10.4103/0253-7613.96346 Text en Copyright: © Indian Journal of Pharmacology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communication
Ye, Hong-bo
Li, Jin-heng
Rui, Jian-zhong
Zheng, Hong
Zhang, Xin-an
Chi, Xin-jin
Chen, Wen-ying
Xu, Jian-guo
Propofol pharmacokinetics in China: A multicentric study
title Propofol pharmacokinetics in China: A multicentric study
title_full Propofol pharmacokinetics in China: A multicentric study
title_fullStr Propofol pharmacokinetics in China: A multicentric study
title_full_unstemmed Propofol pharmacokinetics in China: A multicentric study
title_short Propofol pharmacokinetics in China: A multicentric study
title_sort propofol pharmacokinetics in china: a multicentric study
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371467/
https://www.ncbi.nlm.nih.gov/pubmed/22701254
http://dx.doi.org/10.4103/0253-7613.96346
work_keys_str_mv AT yehongbo propofolpharmacokineticsinchinaamulticentricstudy
AT lijinheng propofolpharmacokineticsinchinaamulticentricstudy
AT ruijianzhong propofolpharmacokineticsinchinaamulticentricstudy
AT zhenghong propofolpharmacokineticsinchinaamulticentricstudy
AT zhangxinan propofolpharmacokineticsinchinaamulticentricstudy
AT chixinjin propofolpharmacokineticsinchinaamulticentricstudy
AT chenwenying propofolpharmacokineticsinchinaamulticentricstudy
AT xujianguo propofolpharmacokineticsinchinaamulticentricstudy